GoAI
Get started
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc.

ELTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.04

−$0.035 · -1.14%

Aug 21, 4:00 PM ET

ELTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

26

Expensive

Momentum

19

Strong Down

Sentiment

41

Mixed

Risk resilience

24

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Robert T. Connelly
Listed since
Feb 5, 2021
Employees
33

Market position

Day range

Current $3.04

52-week range

Current $3.04

Open
$3.10
Previous close
$3.075
Volume
279.37K
0.17× average
Average volume
1.61M
Average daily volume
Market cap
57.96M USD
Beta
1.88
Market reference 1
50-day average
$3.7806
-19.59% below average
200-day average
$8.3328
-63.52% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
117.84M USD
P/E (TTM)
-1.43×
P/B (TTM)
7.37×
P/S (TTM)
0×
EV / EBITDA
-3.16×
Earnings yield
-32.46%
Free cash flow yield
-30.33%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-2418.77%
Return on assets
-153.01%
Return on invested capital
-201.00%

Financial health

Debt / equity
1.78×
Current ratio
2.38×

Financial statements

Income trends

Operating income

−37.71M USD+16.17%

Net income

−39.57M USD+23.75%
Income trends across reported periods−20.92M USD−32.18M USD−43.45M USD−54.71M USDOperating income, FY2021: −39.31M USDOperating income, FY2022: −23.73M USDOperating income, FY2023: −35.75M USDOperating income, FY2024: −44.99M USDOperating income, FY2025: −37.71M USDNet income, FY2021: −26.4M USDNet income, FY2022: −28.21M USDNet income, FY2023: −35.2M USDNet income, FY2024: −51.9M USDNet income, FY2025: −39.57M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −39.31M USD. Operating income FY2022 −23.73M USD. Operating income FY2023 −35.75M USD. Operating income FY2024 −44.99M USD. Operating income FY2025 −37.71M USD. Net income FY2021 −26.4M USD. Net income FY2022 −28.21M USD. Net income FY2023 −35.2M USD. Net income FY2024 −51.9M USD. Net income FY2025 −39.57M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue————28.31M USD
Cost of goods sold1.13M USD1.18M USD1.17M USD1.06M USD1.23M USD
Gross profit−1.13M USD−1.18M USD−1.17M USD−1.06M USD27.08M USD
Research and development24.9M USD33.66M USD22.68M USD17.05M USD48.61M USD
Selling, general, and administrative12.81M USD11.33M USD11.9M USD5.63M USD17.78M USD
Operating expenses36.59M USD43.81M USD34.58M USD22.68M USD66.39M USD
Interest income776K USD777K USD373K USD64.83K USD3.39K USD
Interest expense1.13M USD455K USD1.06M USD3.6M USD876.44K USD
Depreciation and amortization1.13M USD1.18M USD1.17M USD1.06M USD801K USD
Operating income−37.71M USD−44.99M USD−35.75M USD−23.73M USD−39.31M USD
Net income−39.57M USD−51.9M USD−35.2M USD−28.21M USD−26.4M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-2.58
FY2025
Latest fiscal-year revenue
0 USD
FY2025
Next fiscal-year EPS consensus
-2.04
FY2026 · 3 analysts
Next fiscal-year revenue consensus
20M USD
FY2026 · 4 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.54-6.68-13.9-21.13FY21FY22FY23FY24FY25FY26FY27

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend31.14M19.82M8.49M-2.83MFY21FY22FY23FY24FY25FY26

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$17.00

459.21% upside
Past 12 months12-month forecastHigh $17.00Average $17.00Low $17.00

Corporate actions

Corporate action history

Stock split

Effective Jun 2, 2023

1:10

ELTX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ELTX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.16M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
965.01K
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
402.07K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
374.21K
Weight
0.00%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
207.85K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
136.2K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
39.22K
Weight
0.00%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Global X - Russell 2000 ETF logoGlobal X - Russell 2000 ETFRSSL
Market value
18.73K
Weight
—
AUM
1.53B USD
Expense ratio
0.08%
Price / 1D
$117.49+0.86%

Continue in GoAI

Research ELTX

research.disclaimer